Advertisement

Topics

FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)

09:32 EDT 6 Aug 2015 | FDA

The U.S. Food and Drug Administration (FDA) is alerting the public that a patient in Europe diagnosed with possible multiple sclerosis (MS) has developed a rare and serious brain infection after taking the drug Gilenya (fingolimod).

Original Article: FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)

NEXT ARTICLE

More From BioPortfolio on "FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...